A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: tumor
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Recruitment Status

Enrolling By Invitation

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.